A Phase 2 study of TAS-115 in patients with CRPC

A PHASE 2, OPEN LABEL, MULTI-ARM STUDY TO ASSESS THE EFFICACY AND SAFETY OF TAS-115 IN PATIENTS WITH CASTRATION RESISTANT PROSTATE CANCER (CRPC)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080223393

Enrollment

Registered

2016-11-25

Start date

2017-01-23

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patient with castration resistant prostate cancer

Interventions

investigational material(s) Generic name etc : TAS-115 INN of investigational material : pamufetinib Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigationa

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: - Provided written informed consent - Histologically confirmed prostate cancer with adenocarcinoma. - Satisfy the following definition of castration resistance. Castrate serum testosterone level:50 ng/dL or less Bilateral orchiectomy or maintenance on androgen ablation therapy with LHRH agonist or antagonist Disease or PSA progression - Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.

Exclusion criteria

Exclusion criteria: - A serious illness or medical condition. - Hypersensitivity to any drugs similar to TAS-115 in structure or class. - History of other primary malignancy in the last 5 years.

Design outcomes

Primary

Measure	Time frame
efficacy Efficacy Bone Navi	—

Secondary

Measure	Time frame
safety efficacy Efficacy, Safety RECIST(Ver.1.1), PCWG3, CTCAE(Ver.4.03)	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026